表紙
市場調査レポート

CalAsia Pharmaceuticals, Inc. - 製品パイプライン分析

CalAsia Pharmaceuticals, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 256087
出版日 ページ情報 英文 21 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
CalAsia Pharmaceuticals, Inc. - 製品パイプライン分析 CalAsia Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日: 2015年04月29日 ページ情報: 英文 21 Pages
概要

CalAsia Pharmaceuticals, Inc. は、技術開発及びその実践によって、薬らしい小分子の創薬に取り組む製薬会社です。同社はまた中枢神経系/全身性腫瘍、感染症、そして変性中枢神経系障害に関連した治療薬を開発する創薬プログラムを主導しています。

当レポートでは、CalAsia Pharmaceuticals, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

CalAsia Pharmaceuticals, Inc.の基本情報

CalAsia Pharmaceuticals, Inc.の概要

  • 主要情報
  • 企業情報

CalAsia Pharmaceuticals, Inc.:R&Dの概要

  • 主な治療範囲

CalAsia Pharmaceuticals, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

CalAsia Pharmaceuticals, Inc.:パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 創薬中の製品/併用療法モダリティ

CalAsia Pharmaceuticals, Inc.:薬剤プロファイル

  • Small Molecule to Inhibit Hsp90 for Central Nervous System Disorders
  • Small Molecules for Non-Surgical Cataracts and Multiple Sclerosis
  • Small Molecules to Inhibit Hsp90 Alpha and TRAP1 for Brain Cancer
  • Small Molecules to Inhibit Hsp90 for Neurofibromatosis Type 2

CalAsia Pharmaceuticals, Inc.:パイプライン分析

  • 標的別
  • 分子タイプ別
  • 作用機序別

CalAsia Pharmaceuticals, Inc.:休止中のプロジェクト

CalAsia Pharmaceuticals, Inc.:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07027CDB

Summary

Global Markets Direct's, 'CalAsia Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the CalAsia Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CalAsia Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of CalAsia Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of CalAsia Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the CalAsia Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate CalAsia Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of CalAsia Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the CalAsia Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of CalAsia Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of CalAsia Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of CalAsia Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • CalAsia Pharmaceuticals, Inc. Snapshot
    • CalAsia Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • CalAsia Pharmaceuticals, Inc. - Research and Development Overview
  • Key Therapeutic Areas
  • CalAsia Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • CalAsia Pharmaceuticals, Inc. - Pipeline Products Glance
    • CalAsia Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • CalAsia Pharmaceuticals, Inc. - Drug Profiles
    • Small Molecule to Inhibit Hsp90 for Central Nervous System Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit NS2B-NS3 Protease for Dengue and West Nile Virus Infection
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Non-Surgical Cataracts and Multiple Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Hsp90 and TRAP1 for Brain Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Hsp90 for Neurofibromatosis Type 2
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • CalAsia Pharmaceuticals, Inc. - Pipeline Analysis
  • CalAsia Pharmaceuticals, Inc. - Pipeline Products by Target
  • CalAsia Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
  • CalAsia Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • CalAsia Pharmaceuticals, Inc. - Dormant Projects
  • CalAsia Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • CalAsia Pharmaceuticals, Inc., Key Information
  • CalAsia Pharmaceuticals, Inc., Key Facts
  • CalAsia Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • CalAsia Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • CalAsia Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • CalAsia Pharmaceuticals, Inc. - Discovery, 2015
  • CalAsia Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • CalAsia Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • CalAsia Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • CalAsia Pharmaceuticals, Inc. - Dormant Developmental Projects,2015

List of Figures

  • CalAsia Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • CalAsia Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • CalAsia Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top